Treatment with 24hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial

Carubelli, V; Zhang, YH; Metra, M; Lombardi, C; Felker, GM; Filippatos, G; O'Connor, CM; Teerlink, JR; Simmons, P; Segal, R; Malfatto, G; La Rovere, MT; Li, DF; Han, XM; Yuan, ZY; Yao, YL; Li, B; Lau, LF; Bianchi, G; Zhang, J

Carubelli, V (corresponding author), Univ & Civil Hosp Brescia, Div Cardiol, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.; Zhang, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Cardiovasc Dis, Heart Failure Ctr, Heart Failure Care Units HFCU,Fuwai Hosp,Natl Ctr, 167 Bei Li Tu Rd, Beijing 100037, Peoples R China.

EUROPEAN JOURNAL OF HEART FAILURE, 2020; 22 (9): 1684

Abstract

AimIstaroxime is a first-in-class agent which acts through inhibition of the sarcolemmal Na+/K+ pump and activation of the SERCA2a pump. This study as......

Full Text Link